A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma
A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma
复制标题
一种基于旁观者细胞的 GM-CSF 分泌疫苗与低剂量环磷酰胺协同作用，可呈现针对小鼠肝细胞癌的治疗性免疫反应
DOI：
10.1038/cmi.2013.20
复制
发表时间：
2013-07-01
影响因子：
24.1
通讯作者：
Sun, Beicheng
中科院分区：
文献类型：
--
作者：
Chen, Chen;Hou, Jiajie;Sun, Beicheng
分泌粒细胞-巨噬细胞集落刺激因子(GM-CSF)的细胞肿瘤疫苗有助于在小鼠模型和癌症患者中诱导强大的抗肿瘤免疫反应。肝细胞癌是中国最常见的恶性肿瘤之一。我们首次描述了一种GM-CSF释放疫苗策略，它代表着朝着对抗这种类型的癌症迈出的一步。本研究采用小剂量环磷酰胺(CY)联合应用小鼠肝癌旁细胞GM-CSF分泌型疫苗Hepa1-6/B78H1-GM-CSF。免疫学检测表明，在肿瘤攻击和疫苗接种后，细胞抗肿瘤免疫反应被有效激活，肿瘤的发展明显受阻，这依赖于与环磷酰胺的协同作用。抗肝癌疫苗在小鼠模型中的良好结果表明，未来这种治疗方法在肝癌患者中的临床应用是可行的。
Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting cellular tumor vaccines contribute to the induction of potent antitumor immune responses in murine models and patients suffering from cancers. Hepatocellular carcinoma (HCC) is one of the most frequent and malignant cancers in China. We describe, for the first time, a GM-CSF releasing vaccine strategy that represents a step toward combating this type of cancer. In this study, a bystander cell-based GM-CSF secreting vaccine against murine HCC, Hepa1–6/B78H1-GM-CSF, was co-administered with a low dose of cyclophosphamide (CY). After challenging with tumor and vaccination, immunological assays demonstrated that the cellular antitumor immune responses were efficiently activated and that tumor development was significantly retarded, which was dependent on synergy with CY. The promising outcome of the anti-HCC vaccine in the murine model demonstrates the feasibility of a future clinical application for this treatment in HCC patients.